Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofensine SCHEMBL11797224 | 0.99 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Diclofensine SCHEMBL30037569 | 0.99 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL11792580 | 0.87 | SLC6A4 (0.76) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL11803430 | 0.86 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL11799175 | 0.85 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL11797787 | 0.84 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL11794884 | 0.84 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL11796550 | 0.84 | SLC6A4 (0.75) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL11804986 | 0.83 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL11794735 | 0.83 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022117-A1 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2023-01-26 | — | — | US | claimed |
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2021113764-A1 | RNAI-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2021-06-10 | — | — | WO | claimed |
| US-10265380-B2 | Method of administering MANF for the protection of sensory cells | AMARANTUS BIOSCIENCE HOLDINGS, INC. (US) | 2019-04-23 | — | — | US | claimed |
| US-20170072015-A1 | METHODS AND COMPOSITIONS FOR THE PROTECTION OF SENSORY CELLS | UNIVERSITY OF MASSACHUSETTS | 2017-03-16 | — | — | US | claimed |
| EP-3113788-A1 | METHODS AND COMPOSITIONS FOR THE PROTECTION OF SENSORY CELLS | Schwartz, Lawrence M. (US) | 2017-01-11 | — | — | EP | claimed |
| WO-2015134485-A1 | METHODS AND COMPOSITIONS FOR THE PROTECTION OF SENSORY CELLS | SCHWARTZ LAWRENCE M (US) | 2015-09-11 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2111394-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-10-28 | — | — | EP | claimed |
| WO-2008145135-A1 | ANTIDEPRESSIVA FOR TREATMENT OF METABOLIC SYNDROME | AARHUS UNIVERSITET (DK) | 2008-12-04 | — | — | WO | claimed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008084057-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-07-17 | — | — | WO | claimed |
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1687000-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| WO-2005048999-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-3947456-A | ANTIDEPRESSANTS | HOFFMAN-LA ROCHE INC. (US) | 1976-03-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | TPH2, PTGS2, PTGES2 | SLC6A4 33/4885SLC6A2 45/4885SLC6A3 93/4885 |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | CNR1, OPRL1, CNR2 | SLC6A4 20/4885SLC6A2 30/4885SLC6A3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.